Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 159

1.

Staphylococcal Superantigen-like protein 11 mediates neutrophil adhesion and motility arrest, a unique bacterial toxin action.

Chen C, Yang C, Barbieri JT.

Sci Rep. 2019 Mar 12;9(1):4211. doi: 10.1038/s41598-019-40817-x.

2.

Detection of ADP-Ribosylating Bacterial Toxins.

Chen C, Barbieri JT.

Methods Mol Biol. 2018;1813:287-295. doi: 10.1007/978-1-4939-8588-3_20.

PMID:
30097876
3.

Light Chain Diversity among the Botulinum Neurotoxins.

Gardner AP, Barbieri JT.

Toxins (Basel). 2018 Jul 2;10(7). pii: E268. doi: 10.3390/toxins10070268. Review.

4.

Protein Toxins That Utilize Gangliosides as Host Receptors.

Zuverink M, Barbieri JT.

Prog Mol Biol Transl Sci. 2018;156:325-354. doi: 10.1016/bs.pmbts.2017.11.010. Epub 2018 Mar 17. Review.

5.

The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.

Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C, Barbieri JT, Johnson EA.

MBio. 2018 Mar 27;9(2). pii: e00089-18. doi: 10.1128/mBio.00089-18.

6.

Enhancing toxin-based vaccines against botulism.

Przedpelski A, Tepp WH, Zuverink M, Johnson EA, Pellet S, Barbieri JT.

Vaccine. 2018 Feb 1;36(6):827-832. doi: 10.1016/j.vaccine.2017.12.064. Epub 2018 Jan 4.

7.

Protein Structure Facilitates High-Resolution Immunological Mapping.

Zuverink M, Barbieri JT.

Clin Vaccine Immunol. 2017 Dec 5;24(12). pii: e00275-17. doi: 10.1128/CVI.00275-17. Print 2017 Dec. Review.

8.

When Escherichia coli doesn't fit the mold: A pertussis-like toxin with altered specificity.

Chen C, Barbieri JT.

J Biol Chem. 2017 Sep 8;292(36):15159-15160. doi: 10.1074/jbc.H117.796094.

9.

Vaccines against Botulism.

Sundeen G, Barbieri JT.

Toxins (Basel). 2017 Sep 2;9(9). pii: E268. doi: 10.3390/toxins9090268. Review.

10.

Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.

Kroken AR, Blum FC, Zuverink M, Barbieri JT.

Infect Immun. 2016 Dec 29;85(1). pii: e00795-16. doi: 10.1128/IAI.00795-16. Print 2017 Jan.

11.

From GFP to β-lactamase: advancing intact cell imaging for toxins and effectors.

Zuverink M, Barbieri JT.

Pathog Dis. 2015 Dec;73(9):ftv097. doi: 10.1093/femspd/ftv097. Epub 2015 Oct 22. Review.

12.

Solubility of the catalytic domains of Botulinum neurotoxin serotype E subtypes.

Chen S, Barbieri JT.

Protein Expr Purif. 2016 Feb;118:18-24. doi: 10.1016/j.pep.2015.10.003. Epub 2015 Oct 22.

PMID:
26477500
13.

Heat-Labile Enterotoxin IIa, a Platform To Deliver Heterologous Proteins into Neurons.

Chen C, Przedpelski A, Tepp WH, Pellett S, Johnson EA, Barbieri JT.

MBio. 2015 Aug 11;6(4):e00734. doi: 10.1128/mBio.00734-15.

14.

Mutations of the functional ARH1 allele in tumors from ARH1 heterozygous mice and cells affect ARH1 catalytic activity, cell proliferation and tumorigenesis.

Kato J, Vekhter D, Heath J, Zhu J, Barbieri JT, Moss J.

Oncogenesis. 2015 Jun 1;4:e151. doi: 10.1038/oncsis.2015.5.

15.

A Heterologous Reporter Defines the Role of the Tetanus Toxin Interchain Disulfide in Light-Chain Translocation.

Zuverink M, Chen C, Przedpelski A, Blum FC, Barbieri JT.

Infect Immun. 2015 Jul;83(7):2714-24. doi: 10.1128/IAI.00477-15. Epub 2015 Apr 20.

16.

Nonenzymatic conversion of ADP-ribosylated arginines to ornithine alters the biological activities of human neutrophil peptide-1.

Stevens LA, Barbieri JT, Piszczek G, Otuonye AN, Levine RL, Zheng G, Moss J.

J Immunol. 2014 Dec 15;193(12):6144-51. doi: 10.4049/jimmunol.1303068. Epub 2014 Nov 12.

17.

Multiple domains of tetanus toxin direct entry into primary neurons.

Blum FC, Tepp WH, Johnson EA, Barbieri JT.

Traffic. 2014 Oct;15(10):1057-65. doi: 10.1111/tra.12197. Epub 2014 Aug 11.

18.

Novel bacterial ADP-ribosylating toxins: structure and function.

Simon NC, Aktories K, Barbieri JT.

Nat Rev Microbiol. 2014 Sep;12(9):599-611. doi: 10.1038/nrmicro3310. Epub 2014 Jul 14. Review.

19.

Bacillus cereus Certhrax ADP-ribosylates vinculin to disrupt focal adhesion complexes and cell adhesion.

Simon NC, Barbieri JT.

J Biol Chem. 2014 Apr 11;289(15):10650-9. doi: 10.1074/jbc.M113.500710. Epub 2014 Feb 26.

20.

Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells.

Blum FC, Przedpelski A, Tepp WH, Johnson EA, Barbieri JT.

Infect Immun. 2014 Feb;82(2):873-81. doi: 10.1128/IAI.01539-13. Epub 2013 Dec 9.

21.

The chaperone protein SmgGDS interacts with small GTPases entering the prenylation pathway by recognizing the last amino acid in the CAAX motif.

Schuld NJ, Vervacke JS, Lorimer EL, Simon NC, Hauser AD, Barbieri JT, Distefano MD, Williams CL.

J Biol Chem. 2014 Mar 7;289(10):6862-76. doi: 10.1074/jbc.M113.527192. Epub 2014 Jan 10.

22.

Exoenzyme S ADP-ribosylates Rab5 effector sites to uncouple intracellular trafficking.

Simon NC, Barbieri JT.

Infect Immun. 2014 Jan;82(1):21-8. doi: 10.1128/IAI.01059-13. Epub 2013 Oct 7.

23.

Pseudomonas aeruginosa utilizes the type III secreted toxin ExoS to avoid acidified compartments within epithelial cells.

Heimer SR, Evans DJ, Stern ME, Barbieri JT, Yahr T, Fleiszig SM.

PLoS One. 2013 Sep 18;8(9):e73111. doi: 10.1371/journal.pone.0073111. eCollection 2013.

24.

Enhancing the protective immune response against botulism.

Przedpelski A, Tepp WH, Kroken AR, Fu Z, Kim JJ, Johnson EA, Barbieri JT.

Infect Immun. 2013 Jul;81(7):2638-44. doi: 10.1128/IAI.00382-13. Epub 2013 May 13.

25.

The C-terminus of Botulinum A Protease Has Profound and Unanticipated Kinetic Consequences Upon the Catalytic Cleft.

Silhár P, Lardy MA, Hixon MS, Shoemaker CB, Barbieri JT, Struss AK, Lively JM, Javor S, Janda KD.

ACS Med Chem Lett. 2013 Feb 14;4(2):283-287. Epub 2012 Dec 23.

26.

General aspects and recent advances on bacterial protein toxins.

Lemichez E, Barbieri JT.

Cold Spring Harb Perspect Med. 2013 Feb 1;3(2):a013573. doi: 10.1101/cshperspect.a013573. Review.

27.

Botulinum neurotoxin serotype C associates with dual ganglioside receptors to facilitate cell entry.

Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT.

J Biol Chem. 2012 Nov 23;287(48):40806-16. doi: 10.1074/jbc.M112.404244. Epub 2012 Oct 1.

28.

Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial.

Anstead M, Heltshe SL, Khan U, Barbieri JT, Langkamp M, Döring G, Dharia S, Gibson RL, Treggiari MM, Lymp J, Rosenfeld M, Ramsey B.

J Cyst Fibros. 2013 Mar;12(2):147-53. doi: 10.1016/j.jcf.2012.08.001. Epub 2012 Sep 1.

29.

Host cell cytotoxicity and cytoskeleton disruption by CerADPr, an ADP-ribosyltransferase of Bacillus cereus G9241.

Simon NC, Vergis JM, Ebrahimi AV, Ventura CL, O'Brien AD, Barbieri JT.

Biochemistry. 2013 Apr 2;52(13):2309-18. doi: 10.1021/bi300692g. Epub 2013 Mar 20.

30.

Vaccines against botulism.

Karalewitz AP, Barbieri JT.

Curr Opin Microbiol. 2012 Jun;15(3):317-24. doi: 10.1016/j.mib.2012.05.009. Epub 2012 Jun 12. Review.

PMID:
22694934
31.

Insights into the different catalytic activities of Clostridium neurotoxins.

Chen S, Karalewitz AP, Barbieri JT.

Biochemistry. 2012 May 8;51(18):3941-7. doi: 10.1021/bi3000098. Epub 2012 Apr 24.

32.

Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system.

Blum FC, Chen C, Kroken AR, Barbieri JT.

Infect Immun. 2012 May;80(5):1662-9. doi: 10.1128/IAI.00057-12. Epub 2012 Mar 5.

33.

Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor.

Zhao J, Du Y, Horton JR, Upadhyay AK, Lou B, Bai Y, Zhang X, Du L, Li M, Wang B, Zhang L, Barbieri JT, Khuri FR, Cheng X, Fu H.

Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16212-6. doi: 10.1073/pnas.1100012108. Epub 2011 Sep 9.

34.

Adenylate cyclase activity of Pseudomonas aeruginosa ExoY can mediate bleb-niche formation in epithelial cells and contributes to virulence.

Hritonenko V, Mun JJ, Tam C, Simon NC, Barbieri JT, Evans DJ, Fleiszig SM.

Microb Pathog. 2011 Nov;51(5):305-12. doi: 10.1016/j.micpath.2011.08.001. Epub 2011 Aug 9.

35.

Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT.

Vaccine. 2011 Oct 13;29(44):7688-95. doi: 10.1016/j.vaccine.2011.07.134. Epub 2011 Aug 10.

36.

Novel ganglioside-mediated entry of botulinum neurotoxin serotype D into neurons.

Kroken AR, Karalewitz AP, Fu Z, Kim JJ, Barbieri JT.

J Biol Chem. 2011 Jul 29;286(30):26828-37. doi: 10.1074/jbc.M111.254086. Epub 2011 Jun 1.

37.

Unique ganglioside binding by botulinum neurotoxins C and D-SA.

Kroken AR, Karalewitz AP, Fu Z, Baldwin MR, Kim JJ, Barbieri JT.

FEBS J. 2011 Dec;278(23):4486-96. doi: 10.1111/j.1742-4658.2011.08166.x. Epub 2011 May 31. Review.

38.

Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.

Chen S, Barbieri JT.

J Biol Chem. 2011 Apr 29;286(17):15067-72. doi: 10.1074/jbc.M111.224493. Epub 2011 Mar 4.

39.

Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1.

Pier CL, Chen C, Tepp WH, Lin G, Janda KD, Barbieri JT, Pellett S, Johnson EA.

FEBS Lett. 2011 Jan 3;585(1):199-206. doi: 10.1016/j.febslet.2010.11.045. Epub 2010 Nov 30.

40.

Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.

Eubanks LM, Silhár P, Salzameda NT, Zakhari JS, Xiaochuan F, Barbieri JT, Shoemaker CB, Hixon MS, Janda KD.

ACS Med Chem Lett. 2010;1(6):268-272.

41.

The ADP-ribosylation domain of Pseudomonas aeruginosa ExoS is required for membrane bleb niche formation and bacterial survival within epithelial cells.

Angus AA, Evans DJ, Barbieri JT, Fleiszig SM.

Infect Immun. 2010 Nov;78(11):4500-10. doi: 10.1128/IAI.00417-10. Epub 2010 Aug 23.

42.

Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA .

Karalewitz AP, Kroken AR, Fu Z, Baldwin MR, Kim JJ, Barbieri JT.

Biochemistry. 2010 Sep 21;49(37):8117-26. doi: 10.1021/bi100865f.

43.

Structural analysis of botulinum neurotoxin type G receptor binding .

Schmitt J, Karalewitz A, Benefield DA, Mushrush DJ, Pruitt RN, Spiller BW, Barbieri JT, Lacy DB.

Biochemistry. 2010 Jun 29;49(25):5200-5. doi: 10.1021/bi100412v.

44.

Toxins from bacteria.

Henkel JS, Baldwin MR, Barbieri JT.

EXS. 2010;100:1-29. Review.

45.

Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors.

Silhár P, Capková K, Salzameda NT, Barbieri JT, Hixon MS, Janda KD.

J Am Chem Soc. 2010 Mar 10;132(9):2868-9. doi: 10.1021/ja910761y.

46.

Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease.

Stowe GN, Silhár P, Hixon MS, Silvaggi NR, Allen KN, Moe ST, Jacobson AR, Barbieri JT, Janda KD.

Org Lett. 2010 Feb 19;12(4):756-9. doi: 10.1021/ol902820z.

47.

Benzylidene cyclopentenediones: First irreversible inhibitors against botulinum neurotoxin A's zinc endopeptidase.

Capková K, Hixon MS, Pellett S, Barbieri JT, Johnson EA, Janda KD.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):206-8. doi: 10.1016/j.bmcl.2009.10.129. Epub 2009 Oct 31.

48.

Synthetic substrate for application in both high and low throughput assays for botulinum neurotoxin B protease inhibitors.

Salzameda NT, Barbieri JT, Janda KD.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5848-50. doi: 10.1016/j.bmcl.2009.08.079. Epub 2009 Aug 27.

49.

Gangliosides as high affinity receptors for tetanus neurotoxin.

Chen C, Fu Z, Kim JJ, Barbieri JT, Baldwin MR.

J Biol Chem. 2009 Sep 25;284(39):26569-77. doi: 10.1074/jbc.M109.027391. Epub 2009 Jul 14.

50.

Proteomic identification of OprL as a seromarker for initial diagnosis of Pseudomonas aeruginosa infection of patients with cystic fibrosis.

Rao AR, Laxova A, Farrell PM, Barbieri JT.

J Clin Microbiol. 2009 Aug;47(8):2483-8. doi: 10.1128/JCM.02182-08. Epub 2009 Jun 24.

Supplemental Content

Loading ...
Support Center